Nika Pharmaceuticals, Inc. engages in the acquisition, development, production, and distribution of pharmaceutical and dietary supplement products. Following a change of control in 2022, the company secured exclusive rights to produce and distribute Thymus Nuclear Glycoprotein for HIV treatment, and the dietary supplements Carotilen, and Physiolong. It also obtained rights to the Inactivated Pepsin Fraction platform for medicinal products, and to 6 additional dietary…
Nika Pharmaceuticals, Inc. engages in the acquisition, development, production, and distribution of pharmaceutical and dietary supplement products. Following a change of control in 2022, the company secured exclusive rights to produce and distribute Thymus Nuclear Glycoprotein for HIV treatment, and the dietary supplements Carotilen, and Physiolong. It also obtained rights to the Inactivated Pepsin Fraction platform for medicinal products, and to 6 additional dietary supplements Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron. The company entered into joint development, and profit sharing agreements with Nika BioTechnology Inc, and Immunotech Laboratories BG Ltd to advance TNG, Carotelin, Physiolong, and IPF based products. Nika Pharmaceuticals, Inc. holds a 40% equity stake in Nika Europe Ltd which is building a pharmaceutical factory to manufacture injectable tablet, and other dosage forms for future product supply. The company's common stock trades on the OTC Markets PINK under the ticker NIKA after a voluntary symbol change in May 2024.
Revenue comes from the sale of Thymus Nuclear Glycoprotein, Carotelin, Physiolong, and IPF based medicinal products sold under the exclusive rights agreements signed in 2022. The company also earns income from profit sharing arrangements with Nika BioTechnology Inc, and Immunotech Laboratories BG Ltd for the joint development of TNG, Carotelin, Physiolong, and IPF based products. Additional revenue is generated from the exclusive rights to distribute 6 dietary supplements Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron in Europe, Asia, Africa, South America, North America, and Australia. Future revenue may arise from the pharmaceutical factory being constructed by Nika Europe Ltd which will allow Nika Pharmaceuticals, Inc. to produce and sell injectable tablet, and other dosage forms.
Nika Pharmaceuticals, Inc. operates in the pharmaceutical, and dietary supplement sectors where it faces competition from large multinational drug makers, and niche supplement brands. Its competitive position is strengthened by exclusive long term rights to proprietary technologies such as the Thymus Nuclear Glycoprotein formulation, and the Inactivated Pepsin Fraction platform. Partnerships with Nika BioTechnology Inc, and Immunotech Laboratories BG Ltd provide shared development costs, and profit sharing which improve financial flexibility. The planned manufacturing footprint in Europe through Nika Europe Ltd gives the company control over supply chain, and potential cost advantages versus reliance on third party contractors. These factors allow Nika Pharmaceuticals, Inc. to differentiate its HIV therapeutic, and supplement offerings in a crowded market.
The company's products are aimed at hospitals, and healthcare providers treating patients with HIV as well as at consumers seeking dietary supplements for immunity, convalescence, and sports performance. Distribution rights cover Europe, Asia, Africa, South America, North America, and Australia providing a broad geographic reach without disclosure of specific customer names. Potential customers include inpatient clinics, outpatient clinics, retail pharmacies, and online supplement sellers.